Acyclovir phosphonate [9-(3-phosphono-propyloxymethyl)guanine; SR3722] and the S enantiomer (SR3772), R enantiomer (SR3773), and R,S enantiomeric mixture (SR3745A) of ganciclovir phosphonate {9-[((-'-)-1-hydroxymethyl-3-phosphono)propyloxymethyl]guanine} were evaluated for their antiviral activities against murine cytomegalovirus. In severe combined immunodeficient mice infected with murine cytomegalovirus, SR3773 and SR3745A (12.5, 25, and 50 mg/kg of body weight per day) were superior to ganciclovir in extending the mean time to death, whereas SR3722 and SR3772 was less potent than ganciclovir. In normal BALB/c mice, SR3773 and ganciclovir were approximately equally active in preventing death. SR3773 caused renal tubular damage when administered at 50 mg/kgday for 15 days. These results suggest that SR3773 may have potential for use in the treatment of human cytomegalovirus infections, but it may also exhibit renal toxicity.
toxicity.
Two antiviral drugs are approved for the treatment of human cytomegalovirus (HCMV) disease, ganciclovir (GCV) and foscarnet. Both compounds have toxic side effects which limit their usefulness (3, 19) , and the emergence of drugresistant viruses is a concern (6, 7). Thus, the need for safer and more effective anti-HCMV agents is apparent. Newer anti-HCMV compounds still in preclinical development include acyclic phosphonate derivatives of nucleosides such as (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (HPMPC) (18) .
We and others reported that phosphonate derivatives of acyclovir and GCV inhibited HCMV and other animal CMVs (1, 5, 12, 13) . Many of these nucleotide analogs were approximately as active as GCV in inhibiting HCMV in cell culture (causing 50% inhibition of viral plaques or cytopathology when used at between S and 20 ,uM, depending on the virus strain). Until recently, the most potent of these agents, {9-[((±)-1-hydroxymethyl-3-phosphono)propyloxymethyl]guanine; SR3745A or ganciclovir homophosphonate [5] } was available only as a mixture of R and S enantiomers. One of the two enantiomers (the R enantiomer) was believed to be responsible for the anti-HCMV activity and the other enantiomer (the S enantiomer) was presumed to be inactive. This hypothesis was based on earlier studies of ganciclovir homophosphonate phosphorylation (5) . The R enantiomer approximates 2'-deoxyguanosine-5'-monophosphate in structure more closely than does the S enantiomer, and therefore should interact more readily with cellular enzymes. Methods have recently been devised to synthesize the chiral R (SR3773) and S (SR3772) enantiomers (11) .
This report describes antiviral evaluations of SR3745A, SR3772, and SR3773 in cell culture and in two murine CMV (MCMV) animal models (14, 17) of HCMV infection. Previously, SR3745A was shown to be beneficial against MCMV infection in mice (5) , and so the likelihood that the chiral R (SR3773) or S (SR3772) compounds would be found to be active was high. Another nucleotide analog evaluated for comparison, 9-(3-phosphonopropyloxymethyl)guanine (SR3722 or acyclovir phosphonate), has never been assessed in animals, although its 3'-ethylphosphono derivative was recently reported to be active against MCMV in vivo (1). The 3'-ethylphosphono derivative is considered to be a prodrug of SR3722.
For these studies, GCV (Cytovene; Syntex Corp., Palo Alto, Calif.), a positive control for most antiviral evaluations, was purchased from a local pharmacy. HPMPC, a control for the intermittent therapy and toxicological studies, was provided by Norbert Bischofberger of Gilead Sciences, Foster City, Calif. The compounds synthesized at SRI International, Menlo Park, Calif., included SR3722, SR3745A, SR3772, and SR3773. All of these substances were prepared as 4 mM stock solutions and were stored frozen in cell culture medium for in vitro antiviral evaluations or were made up in sterile saline for animal studies.
A guanylate kinase assay was used as a means of determining the enantiomeric purities of SR3772 and SR3773. On the basis of work previously reported by Duke et (17) . Because of the rapid evolution of disease in BALB/c mice, treatments were administered twice or four times daily for 5 days. Treatments in SCID mice were administered daily for 1 week on the basis of good responses against MCMV infection by once-daily treatments with GCV and HPMPC (8, 17) . Because the phosphonates used in the experiments described here are poorly absorbed by the intestinal tract (less than 3% orally bioavailable [unpublished data]), treatments were administered by i.p. inoculation starting at 24 h after virus challenge. The parameters used to assess antiviral activity included the prevention of mortality and/or extensions in the mean day to death. Statistical interpretations of these parameters were made by two-tailed Fisher exact (mortality) and Mann-Whitney U (mean day to death) tests. SR3773 and GCV were approximately equally active when they were administered to the animals twice daily (Table 2) .
However, on the basis of EC50s and ECgos, GCV was half as active when it was given four times daily. These results were obtained from a single experiment in which the two treatment regimens were evaluated in parallel, thus minimizing biological variability. In terms of actual survival at particular doses, twice-daily dosing with GCV at 6.25 and 12.5 mg/kg of body weight per day gave 80 and 100% protection, respectively, whereas four-times-daily dosing afforded only 10 and 70% protection, respectively. In BALB/c mice, SR3722 and SR3772 were 6-to 10-fold less potent than SR3773. For the compounds tested, a comparison of EC50s and ECgs showed that the majority of the EC90s were only twofold greater than the EC50s, indicating sharp dose-response curves.
Mortality caused by MCMV infections could not be prevented in SCID mice, but the mean survival time was extended by treatment with the SR compounds and GCV (Table 3 ). The extension of the life span by GCV treatments paralleled that found in previous studies (17) . At equivalent doses, SR3773 was markedly more active than GCV (Table 3 , experiment 1), since the lowest (12.5 mg/kg/day) dose of SR3773 caused a significantly longer (P < 0.05) extension in longevity than the highest (50 mg/kg/day) dose of GCV. SR3772 was only weakly effective at the highest (50 mg/kg/day) dose tested in comparison with the effectiveness of the placebo control. Approximately twice as much SR3745A as SR3773 was needed to cause the same degree of extension in mean survival time (Table 3 , experiment 2). These results suggest that the SR3772 component present in the SR3745A mixture was inactive at the doses tested. To test this hypothesis directly, when SR3772 was evaluated in SCID mice (Table 3, moderate increases in longevity when administered at 50 and 100 mg/kg/day. The 25-mg/kg/day dosage of SR3772 was inactive, which was the amount present in the dosage of 50 mg of SR3745A per kg/day used previously (Table 3, experiment  2) .
In a final MCMV experiment the efficacies of intermittent treatments with SR3773 and HPMPC on the survival of SCID mice were compared (Table 3 , experiment 4). Experimental designs were based on reports that HPMPC is effective in delaying MCMV-induced mortality when given as infrequently as once weekly (9, 17) . Infrequent dosing resulted in greater than 20 (SR3773) or 30 (HPMPC) days of increase in the life span compared with the life spans of the placebo-treated control group. HPMPC was more effective than SR3773 in delaying mortality (P < 0.05, comparing the respective drugtreated groups). For each compound, the effect of 50 mg/kg given once weekly was approximately the same as that of 25 mg/kg administered twice weekly.
From toxicology research conducted on the SR compounds in rats (unpublished data), there was an indication that the SR family of compounds caused renal toxicity. To investigate this further in mice, the SR compounds were evaluated for their toxicities by using the highest dose of each substance tested in the antiviral experiments (Table 4) . Five uninfected BALB/c mice (weights, 11 to 12 g) in each dosage group were treated with the SR compounds or HPMPC (which is known to cause renal toxicity in humans [4] ) once daily for 15 days. The 10-mg/kg/day dosage of HPMPC was selected on the basis of its relative equivalence in potency (17) to that of SR3773 (50 mg/kg/day) in SCID mice. Weights were recorded every 2 to 3 days during the course of treatment and 1 day later. At 16 days the animals were sacrificed, blood was collected for serum analysis, and the kidneys were placed in 10% buffered Formalin fixative. The kidneys were sent to the Utah State University Diagnostic Laboratory (Logan, Utah) for thin sectioning and histological examination by a board-certified pathologist. A report of the status of each group of kidneys was sent back to us. Blood urea nitrogen levels in serum were assayed by using a commercially available kit (Sigma) adapted to a 96-well plate format. None of the compounds at any dosage tested appeared to be toxic except SR3773, which induced weight loss, caused an elevation in the blood urea nitrogen levels (an indication of kidney damage), and caused destruction of the proximal tubular epithelium with accompanying mineralization of the affected proximal kidney tubules. Apparently, the 10-mg/kg/ day dosage of HPMPC was less than the toxic level since no abnormalities were noted in the mice that received that treatment. Although SR3773 exhibited the most striking antiviral activity in vivo among the compounds tested, it also proved to be toxic to the kidneys at the 50-mg/kg dose tested. We assume that a 25-mg/kg/day dosage given for 15 days would not be toxic, however. This conclusion is based on the results of treatment with 50 mg of SR3745A per kg/day (which contained about 50% SR3773 and 50% SR3772), which was well tolerated by the mice (Table 4) . By making this extrapolation we are assuming that the presence of SR3772 did not somehow attenuate the toxicity of SR3773 in vivo. From unpublished studies in rats, the renal toxicity of SR3773 is not due to crystallization of drug in the kidney (the aqueous solubility of SR3773 exceeds 10 mg/ml). Rather, SR3773 causes a direct killing of the renal tubular cells by an undefined mechanism. The toxicity of SR3773 in mice exceeded that of HPMPC, although the dosage of HPMPC was fivefold lower. HPMPC was not lethal to mice treated with 75 mg/kg/day for 10 days but did induce weight loss (17) , indicating toxicity at this dosage.
The in vitro potencies of SR3745A and SR3773 are about 10-to 20-fold greater against MCMV than against HCMV (5, 11) (unpublished data). Similarly, HPMPC is reported to be 10-fold more active against MCMV than HCMV in cell culture (2) . Comparatively, the potency of HPMPC against HCMV (reported to be 0.2 ,uM [2] ) exceeds those of SR3745A and SR3773 (4 to 6 ,uM [5, 11] [unpublished data]) by 20-to 30-fold. It may be expected that higher doses of these SR compounds than of HPMPC would be required to treat HCMV in humans, which implies greater potential for toxicity. 
